Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results
- PMID: 26909259
- PMCID: PMC4723346
- DOI: 10.1016/j.jbo.2012.10.003
Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results
Abstract
Background: Bone-targeted agents are widely used for the treatment of osteoporosis, the prevention of cancer-therapy induced bone loss, and for reducing the risk of skeletal related events in patients with metastatic disease. Despite widespread use, relatively little is known about the in vivo effect of these agents on bone homeostasis, bone quality, and bone architecture in humans. Traditionally bone quality has been assessed using a transiliac bone biopsy with a 7 mm "Bordier" core needle. We examined the possibility of using a 2 mm "Jamshidi" core needle as a more practical and less invasive method to assess bone turnover and potentially other tumor effects.
Methods: A pilot study on the feasibility of assessing bone quality and microarchitecture and tumor invasion using a 2 mm bone marrow trephine was conducted. Patients underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate. Samples were analyzed for bone microarchitecture, bone density, and histomorphometry. The study plan was to accrue three patients with advanced breast cancer to assess the feasibility of the study before enrolling more patients.
Results: The procedure was well tolerated. The sample quality was excellent to analyze bone trabecular microarchitecture using both microCT and histomorphometry. Intense osteoclastic activity was observed in a patient with extensive tumor burden in bone despite intravenous bisphosphonate therapy.
Discussion: Given the success of this study for assessing bone microarchitecture, bone density, and histomorphometry assessment using a 2 mm needle the study will be expanded beyond these initial three patients for longitudinal assessment of bone-targeted therapy.
Keywords: Bisphosphonate; Breast cancer; Histomorphometry; MicroCT; Microarchitecture.
Figures


Similar articles
-
Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec. Bone Rep. 2021. PMID: 34841014 Free PMC article.
-
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.J Bone Miner Res. 2005 Sep;20(9):1548-61. doi: 10.1359/JBMR.050411. Epub 2005 Apr 27. J Bone Miner Res. 2005. PMID: 16059627 Free PMC article.
-
Side-to-side and within-side variability of 3D bone microarchitecture by conventional micro-computed tomography of paired iliac crest biopsies.Bone. 2008 Jul;43(1):203-208. doi: 10.1016/j.bone.2008.02.019. Epub 2008 Mar 18. Bone. 2008. PMID: 18439891
-
Bone microarchitecture evaluated by histomorphometry.Micron. 2005;36(7-8):609-16. doi: 10.1016/j.micron.2005.07.007. Epub 2005 Sep 6. Micron. 2005. PMID: 16242341 Review.
-
Trabecular bone microarchitecture: a review.Morphologie. 2008 Dec;92(299):162-70. doi: 10.1016/j.morpho.2008.10.003. Epub 2008 Nov 18. Morphologie. 2008. PMID: 19019718 Review.
Cited by
-
Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting.J Bone Oncol. 2015 Jun 23;4(2):54-8. doi: 10.1016/j.jbo.2015.06.001. eCollection 2015 Jun. J Bone Oncol. 2015. PMID: 26579489 Free PMC article. Review.
-
Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.J Bone Oncol. 2014 Feb 4;3(1):1-4. doi: 10.1016/j.jbo.2014.01.001. eCollection 2014 Mar. J Bone Oncol. 2014. PMID: 26909291 Free PMC article.
-
Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.J Bone Oncol. 2016 Jul 7;5(4):180-184. doi: 10.1016/j.jbo.2016.07.001. eCollection 2016 Nov. J Bone Oncol. 2016. PMID: 28008380 Free PMC article.
-
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.J Clin Med. 2013 Aug 19;2(3):67-88. doi: 10.3390/jcm2030067. J Clin Med. 2013. PMID: 26237063 Free PMC article. Review.
-
Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec. Bone Rep. 2021. PMID: 34841014 Free PMC article.
References
-
- Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone. 2011;49(1):71–76. - PubMed
-
- Lewiecki E.M. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 2011;71(6):791–814. - PubMed
-
- Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. New England Journal of Medicine. 2011;364(18):1728–1737. - PubMed
-
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association 2001;285(6):785–795. - PubMed
-
- Rivadeneira F., Zillikens M.C., De Laet C.E., Hofman A., Uitterlinden A.G., Beck T.J. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. Journal of Bone and Mineral Research. 2007;22(11):1781–1790. - PubMed
LinkOut - more resources
Full Text Sources